RT Journal
A1 Kuehn BM
T1 VArenicline safety notice
JF JAMA
JO JAMA
YR 2013
FD January 23
VO 309
IS 4
SP 333
OP 333
DO 10.1001/jama.2013.16
UL http://dx.doi.org/10.1001/jama.2013.16
AB 
After a 2011 clinical trial found an increased risk of serious cardiovascular events among patients with cardiovascular disease using varenicline, the drug's label was revised and the FDA warned the public of the risk (http://tinyurl.com/72zwenq). The agency also required the drug's manufacturer to conduct a meta-analysis of clinical trials of varenicline to compare the risk of major adverse cardiac events (cardiovascular-related death, nonfatal myocardial infarction, and nonfatal stroke) among patients taking the drug and those taking placebo.